These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34652783)

  • 21. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Chapin-Bardales J; Myers T; Gee J; Shay DK; Marquez P; Baggs J; Zhang B; Licata C; Shimabukuro TT
    Vaccine; 2021 Nov; 39(48):7066-7073. PubMed ID: 34763946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study.
    Salmerón Ríos S; Cortés Zamora EB; Avendaño Céspedes A; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Mas Romero M; Tabernero Sahuquillo MT; Blas Señalada JJ; Murillo Romero A; García Nogueras I; Estrella Cazalla JD; Andrés-Pretel F; Lauschke VM; Stebbing J; Abizanda P
    J Am Geriatr Soc; 2022 Mar; 70(3):650-658. PubMed ID: 34894403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
    Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
    Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effects of prior third dose mRNA vaccination in rural nursing home residents during SARS-CoV-2 outbreaks.
    Rhynold ES; Quan S; Orr PH; LaBine L; Singer A; St John PD
    J Am Geriatr Soc; 2022 Nov; 70(11):3245-3249. PubMed ID: 35938635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactogenicity of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19 in workers of a tertiary hospital.
    Palomo-Palomo C; Guerra-Estévez D; Parrado-González A; Estaire-Gutiérrez J; Reyes-Malia M; Romero-Alonso MM
    Farm Hosp; 2022 Mar; 46(3):152-156. PubMed ID: 36183208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents.
    Tuaillon E; Pisoni A; Veyrenche N; Rafasse S; Niel C; Gros N; Muriaux D; Picot MC; Aouinti S; Van de Perre P; Bousquet J; Blain H
    Sci Rep; 2022 Aug; 12(1):13749. PubMed ID: 35962053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers.
    Nachtigall I; Bonsignore M; Hohenstein S; Bollmann A; Günther R; Kodde C; Englisch M; Ahmad-Nejad P; Schröder A; Glenz C; Kuhlen R; Thürmann P; Meier-Hellmann A
    BMC Infect Dis; 2022 Mar; 22(1):291. PubMed ID: 35346089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 BNT162b2 vaccine-induced humoral response and reactogenicity in individuals with prior COVID-19 disease.
    Kelsen SG; Braverman AS; Aksoy MO; Hayman JA; Patel PS; Rajput C; Zhao H; Fisher SG; Ruggieri MR; Gentile NT
    JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35019861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Events Following One Dose of mRNA COVID-19 Vaccination Among US Nursing Home Residents With and Without a Previous SARS-CoV-2 Infection.
    Bardenheier BH; Gravenstein S; Blackman C; Gutman R; Sarkar IN; Feifer RA; White EM; McConeghy K; Nanda A; Bosco E; Mor V
    J Am Med Dir Assoc; 2021 Nov; 22(11):2228-2232. PubMed ID: 34534492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
    Kitagawa H; Kaiki Y; Sugiyama A; Nagashima S; Kurisu A; Nomura T; Omori K; Akita T; Shigemoto N; Tanaka J; Ohge H
    J Infect Chemother; 2022 Apr; 28(4):576-581. PubMed ID: 35058126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan.
    Kageyama T; Ikeda K; Tanaka S; Taniguchi T; Igari H; Onouchi Y; Kaneda A; Matsushita K; Hanaoka H; Nakada TA; Ohtori S; Yoshino I; Matsubara H; Nakayama T; Yokote K; Nakajima H
    Clin Microbiol Infect; 2021 Dec; 27(12):1861.e1-1861.e5. PubMed ID: 34375755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine.
    Levy I; Levin EG; Olmer L; Regev-Yochay G; Agmon-Levin N; Wieder-Finesod A; Indenbaum V; Herzog K; Doolman R; Asraf K; Halperin R; Lustig Y; Rahav G
    Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents.
    Van Praet JT; Vandecasteele S; De Roo A; De Vriese AS; Reynders M
    Clin Infect Dis; 2021 Dec; 73(11):2145-2147. PubMed ID: 33825869
    [No Abstract]   [Full Text] [Related]  

  • 40. COVID-19 Outbreaks in Nursing Homes Despite Full Vaccination with BNT162b2 of a Majority of Residents.
    Lafuente-Lafuente C; Rainone A; Guérin O; Drunat O; Jeandel C; Hanon O; Belmin J;
    Gerontology; 2022; 68(12):1384-1392. PubMed ID: 35313315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.